Viz.ai has expanded its AI-powered healthcare platform into neurodegenerative disease through a collaboration with Cortechs.ai, bringing quantitative MRI analysis for multiple sclerosis to hospitals and health systems across the US.
Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, is collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai’s NeuroQuant and NeuroQuant MS suite into the Viz.ai platform – expanding access to quantitative neuroimaging for hospitals and health systems across the US.
This partnership marks Viz.ai’s expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings.
The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai’s care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale.
“Viz.ai’s core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care team member at the right time to improve patient outcomes,” said Dr. Tim Showalter, Chief Medical Officer, Viz.ai. “This collaboration with Cortechs.ai extends that commitment into neurodegenerative disease, an area with profound unmet need and enormous potential – particularly where earlier patient identification and disease characterization can meaningfully change the treatment trajectory. We see this as the foundation for something much bigger, and we’re just getting started.”
With an established footprint of nearly 2,000 US hospitals, Viz.ai is uniquely positioned alongside Cortechs.ai to ensure patients with neurodegenerative disease reach the right care faster.
“Cortechs.ai is building NeuroQuant into the leading platform for neuro quantification and analysis by providing the trusted intelligence layer that enables healthcare innovators to seamlessly integrate clinically validated quantitative imaging into their own solutions,” said Kyle Frye, CEO, Cortechs.ai. “We believe the future of healthcare AI will be built on connected platforms, not isolated point solutions. Our partnership with Viz.ai is a powerful example of that vision, combining Viz.ai’s care coordination platform with the trusted quantitative insights of NeuroQuant and NeuroQuant MS platforms to accelerate innovation, enhance clinical decision-making, and ultimately improve outcomes for patients.”
